Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
2tQ9rmY06F1f0RpU
